(redirected from Dyslipidemias)
Also found in: Medical.


An abnormal concentration of lipids or lipoproteins in the blood.

dys·lip′i·de′mic (-mĭk) adj.


n dislipidemia
Mentioned in ?
References in periodicals archive ?
ARO-ANG3 is a subcutaneously administered RNA interference-based investigational medicine targeting angiopoietin like protein 3 being developed for the treatment of dyslipidemias, such as HoFH, and metabolic diseases.
Treatment of dyslipidemias to prevent cardiovascular disease in patients with type 2 diabetes.
M2 PHARMA-January 8, 2019-Arrowhead Pharmaceuticals Begins Dosing in Phase 1 Study of ARO-ANG3 for Treatment of Dyslipidemias and Metabolic Diseases
The 2017 update of the Brazilian Dyslipidemia and Atherosclerosis Prevention Guideline introduced changes in the laboratory-based classification of dyslipidemias and their reference values; therapeutic targets are defined based on the individual cardiovascular risk and nutritional status.
Dyslipidemia. Table 1 identifies the various HDL-c, LDLc, and triglyceride categories defining the six mutually exclusive dyslipidemias, including normolipidemia as a reference group.
How well can we control dyslipidemias through lifestyle modifications?
Masroor Ahmad spoke on dyslipidemias. He pointed out that heart disease account for 35% of the disease burden globally.
It is asso-ciated with dyslipidemias and is considered independent cardiovascular risk.
Dyslipidemias are disorders of lipoprotein metabolism, including lipoprotein overproduction or deficiency.
Associations of dyslipidemias from childhood to adulthood with carotid intima-media thickness, elasticity, and brachial flow-mediated dilatation in adulthood: the Cardiovascular Risk in Young Finns Study.
[9] The Task Force for the Management of Dyslipidemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS), "ESC/EAS guidelines for the management of dyslipidemias," European Heart Journal, vol.